Regeneron Pharmaceuticals Inc (REGN.OQ)
14 Dec 2017
PARIS Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday.
* CEO says company on track to sell European generics unit (Adds CEO comments, details, updates shares)
BRIEF-Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous Squamous Cell Carcinoma
* REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
BRIEF-Regeneron Announces FDA Acceptance Of SBLA Filing For 12-Week Dosing Of Eylea(Aflibercept) Injection For Patients With Wet AMD
* REGENERON ANNOUNCES FDA ACCEPTANCE OF SBLA FILING FOR 12-WEEK DOSING OF EYLEA® (AFLIBERCEPT) INJECTION FOR PATIENTS WITH WET AMD
* REGENERON AND DECIBEL THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP THERAPEUTICS FOR HEARING LOSS AND TINNITUS
Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.
Nov 27 Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.
ZURICH, Nov 13 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 9,159 points on Monday, according to premarket indications by bank Julius Baer .
BERLIN/FRANKFURT, Nov 13 The following are some of the factors that may move German stocks on Monday:
ZURICH Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.
|Novartis AG (NOVN.S)||CHF83.80||-0.05|
|Pfizer Inc. (PFE.N)||$37.20||+0.74|
|Bayer AG (BAYGn.DE)||€106.50||+1.40|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€73.55||-0.22|
|Merck & Co., Inc. (MRK.N)||$56.24||+0.23|
|Amgen, Inc. (AMGN.OQ)||$177.04||+2.12|
|Roche Holding Ltd. (ROG.S)||CHF244.10||+2.40|
|Roche Holding Ltd. (RO.S)||CHF243.40||+0.90|
|Eli Lilly and Co (LLY.N)||$86.54||+0.04|